Coherus Oncology (CHRS) Total Non-Current Liabilities (2013 - 2026)
Coherus Oncology (CHRS) posted Total Non-Current Liabilities of $170.4 million for Q1 2026, down 12.83% sequentially from $195.5 million in Q4 2025, and down 67.43% YoY from $523.2 million in Q1 2025.
Coherus Oncology (CHRS) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Total Non-Current Liabilities for 14 years, with the latest figure at $170.4 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 67.43% year-over-year to $170.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $170.4 million (down 67.43% YoY) and the FY2025 annual result came in at $195.5 million, down 64.53% from the prior year.
- Total Non-Current Liabilities declined to $170.4 million in Q1 2026 per CHRS's latest filing, from $195.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $844.8 million in Q1 2024 and troughed at $170.4 million in Q1 2026.
- A 5-year average of $560.0 million and a median of $592.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities soared 41.07% in 2024, then slumped 67.43% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $614.8 million in 2022, then jumped by 31.83% to $810.5 million in 2023, then sank by 31.99% to $551.2 million in 2024, then slumped by 64.53% to $195.5 million in 2025, then slipped by 12.83% to $170.4 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $170.4 million, $195.5 million, and $428.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 9.32 Bn |
| 10 | Coherus Oncology | 213.65 Mn | 108.34 Mn | 10.07 Mn | 112.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112.76 Mn |
| Mar 31, 2026 | 170.43 Mn |
| Dec 31, 2025 | 195.51 Mn |
| Sep 30, 2025 | 428.64 Mn |
| Jun 30, 2025 | 302.90 Mn |
| Mar 31, 2025 | 523.25 Mn |
| Dec 31, 2024 | 551.19 Mn |
| Sep 30, 2024 | 592.34 Mn |
| Jun 30, 2024 | 731.27 Mn |
| Mar 31, 2024 | 844.76 Mn |
| Dec 31, 2023 | 810.47 Mn |
| Sep 30, 2023 | 713.87 Mn |
| Jun 30, 2023 | 644.25 Mn |
| Mar 31, 2023 | 598.83 Mn |
| Dec 31, 2022 | 614.80 Mn |
| Sep 30, 2022 | 647.94 Mn |
| Jun 30, 2022 | 568.53 Mn |
| Mar 31, 2022 | 580.72 Mn |
| Dec 31, 2021 | 580.86 Mn |
| Sep 30, 2021 | 610.22 Mn |